Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Number of patients who ever received a drug from onset to last available follow-up visit, with the corresponding days of drug exposure per medication from the first day of drug administration to the last available follow-up visit

From: Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

   Pharmachild
N = 8274
Days of drug exposure
BiKeR
N = 3990
Days of drug exposure
Sweden
N = 3020
Days of drug exposure
DMARDs Methotrexate 6963 (84.2%);
924 (449–1747)
3344 (83.8%);
494 (173–957)
1842 (61%);
1198 (555–2127)
Sulfasalazine 861 (10.4%);
360 (143–730)
274 (6.9%);
174 (32–470)
95 (3%)
443 (132–1042)
Cyclosporine 518 (6.3%);
616 (235–1358)
113 (2.8%);
186 (62–580)
16 (0.5%);
584 (250–1452)
Leflunomide 372 (4.5%);
434 (182–888)
219 (5.5%);
267 (68–701)
2 (0.1%);
840 (511–1169)
Hydroxychloroquine 279 (3.4%);
486 (202–1022)
106 (2.7%);
182 (1–535)
32 (1.1%);
957 (311–1612)
Azathioprine 108 (1.3%);
439 (187–973)
155 (3.9%);
186 (26–494)
31 (1%);
1171 (340–2179)
Thalidomide 35 (0.4%);
290 (85–665)
0 0
Systemic glucocorticoids   3299 (39.9%)
206 (67–648)
1680 (42.1%)
196 (81–449)
503 (16.7%)
91 (35–437)
Biologics Etanercept 3600 (43.5%);
719 (300–1338)
2467 (61.8%);
489 (184–934)
726 (24%);
827 (341–1666)
Adalimumab 1778 (21.5%);
442 (174–927)
810 (20.3%);
350 (117–755)
657 (21.8%);
701 (292–1604)
Infliximab 705 (8.5%);
425 (160–951)
68 (1.7%);
213 (129–717)
189 (6.3%);
825 (328–1738)
Tocilizumab 633 (7.7%);
351 (126–742)
281 (7%);
377 (127–730)
122 (4%);
660 (193–1353)
Abatacept 420 (5.1%);
342 (156–715)
101 (2.5%);
190 (83–582)
80 (2.6%);
378 (164–1125
Anakinra 339 (4.1%);
299 (94–837)
50 (1.3%);
304 (9–806)
48 (1.6%);
422 (144–836)
Golimumab 161 (1.9%);
270 (106–623)
63 (1.6%);
344 (88–783)
93 (3.1%);
796 (370–1743)
Canakinumab 145 (1.8%);
351 (133–1032)
39 (1%);
364 (214–733)
7 (0.2%);
654 (604–1654)
Rituximab 103 (1.2%);
42 (24–87)
4 (0.1%);
15 (0–108)
20 (0.7%);
129 (15–1550)
Certolizumab 33 (0.4%);
166 (106–309)
4 (0.1%);
49 (0–110)
8 (0.3%);
984 (714–1538)
Other biologic agents 14 (0.2%);
217 (54–432)
4 (0.1%);
77 (25–149)
2 (0.1%);
325 (223–426)
  1. Data are numbers of patients with frequencies (percentage), and medians and 1st–3rd quartiles of days of drug exposure
  2. Abbreviations: BiKeR Biologics in Pediatric Rheumatology Registry, DMARD disease-modifying anti-rheumatic drug